Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis
The aim of this meta-analysis was to assess the safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density (BMD). Safety of denosumab was compared with placebo or bisphosphonates. A systematic literature search without language restriction was conducted up to January,...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical and experimental pathology 2014-01, Vol.7 (5), p.2113-2122 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2122 |
|---|---|
| container_issue | 5 |
| container_start_page | 2113 |
| container_title | International journal of clinical and experimental pathology |
| container_volume | 7 |
| creator | Zhou, Zhenyu Chen, Chen Zhang, Jun Ji, Xinran Liu, Lifeng Zhang, Guichun Cao, Xuecheng Wang, Pingshan |
| description | The aim of this meta-analysis was to assess the safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density (BMD).
Safety of denosumab was compared with placebo or bisphosphonates. A systematic literature search without language restriction was conducted up to January, 2014. The RevMan 5.1 software was used for statistical analysis.
A total of 11 English literatures were eventually identified. The pooled data in the overall analysis revealed that there was no significant difference when compared denosumab with placebo or bisphosphonates in any adverse events (AAE) (RR=0.99, 95% CI=0.98-1.01, p=0.29), serious adverse event (SAE) (RR=1.05, 95% CI=0.98-1.13, p=0.18), neoplasm/cancer (RR=1.14, 95% CI=0.95-1.37, p=0.16) and deaths (RR=0.77, 95% CI=0.57-1.04, p=0.09). However, significant differences were found when compared denosumab with placebo or bisphosphonates in SAE related to infection (RR=1.23, 95% CI=1.00-1.52, p=0.05) and non-vertebral fracture (RR=0.86, 95% CI=0.74-1.00, p=0.05). Subgroup analysis was performed by the type of drugs which was used in the control group. The results of subgroup analysis did not demonstrate the differences between denosumab and bisphosphonates in SAE related to infection (RR=1.13, 95% CI=0.63-2.03) and non-vertebral fracture (RR=1.31, 95% CI=0.87-1.98).
Compared to placebo, denosumab treatment significantly decreased the risk of non-vertebral fracture but increased the risk of SAE related to infection in the postmenopausal women with osteoporosis or low BMD. However, no difference between the safety of denosumab and bisphosphonates was found. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4069896</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24966919</sourcerecordid><originalsourceid>FETCH-LOGICAL-p266t-6785e00dd1c102c3e9438d566a15d9de9d038b1ad64ef6998e85c03c308e20cc3</originalsourceid><addsrcrecordid>eNpVkFtLxDAQhYsg7rr6FyR_oJBLOyY-CLJ4WVjwQX0uaTJ1s7RJabIu_fcGvKBPw8w55-MwJ8WSKQElB14vivMY95QC4xU9Kxa8UgCKqWWxf9EdppmEjlj0IR4G3RLnyRhiGvJh1Ieoe3IMeSFHl3YkCxjGMIXoIgkT6cORtMEjGZzHKXszJ7o03xBNBky61F73czZfFKed7iNefs9V8fZw_7p-KrfPj5v13bYcOUAq4VrWSKm1zDDKjUBVCWlrAM1qqywqS4VsmbZQYQdKSZS1ocIIKpFTY8SquP3ijod2QGvQp1yrGSc36GlugnbNf8W7XfMePpqKgpIKMuDqL-A3-fM18QmfX2vY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis</title><source>MEDLINE</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Zhou, Zhenyu ; Chen, Chen ; Zhang, Jun ; Ji, Xinran ; Liu, Lifeng ; Zhang, Guichun ; Cao, Xuecheng ; Wang, Pingshan</creator><creatorcontrib>Zhou, Zhenyu ; Chen, Chen ; Zhang, Jun ; Ji, Xinran ; Liu, Lifeng ; Zhang, Guichun ; Cao, Xuecheng ; Wang, Pingshan</creatorcontrib><description>The aim of this meta-analysis was to assess the safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density (BMD).
Safety of denosumab was compared with placebo or bisphosphonates. A systematic literature search without language restriction was conducted up to January, 2014. The RevMan 5.1 software was used for statistical analysis.
A total of 11 English literatures were eventually identified. The pooled data in the overall analysis revealed that there was no significant difference when compared denosumab with placebo or bisphosphonates in any adverse events (AAE) (RR=0.99, 95% CI=0.98-1.01, p=0.29), serious adverse event (SAE) (RR=1.05, 95% CI=0.98-1.13, p=0.18), neoplasm/cancer (RR=1.14, 95% CI=0.95-1.37, p=0.16) and deaths (RR=0.77, 95% CI=0.57-1.04, p=0.09). However, significant differences were found when compared denosumab with placebo or bisphosphonates in SAE related to infection (RR=1.23, 95% CI=1.00-1.52, p=0.05) and non-vertebral fracture (RR=0.86, 95% CI=0.74-1.00, p=0.05). Subgroup analysis was performed by the type of drugs which was used in the control group. The results of subgroup analysis did not demonstrate the differences between denosumab and bisphosphonates in SAE related to infection (RR=1.13, 95% CI=0.63-2.03) and non-vertebral fracture (RR=1.31, 95% CI=0.87-1.98).
Compared to placebo, denosumab treatment significantly decreased the risk of non-vertebral fracture but increased the risk of SAE related to infection in the postmenopausal women with osteoporosis or low BMD. However, no difference between the safety of denosumab and bisphosphonates was found.</description><identifier>EISSN: 1936-2625</identifier><identifier>PMID: 24966919</identifier><language>eng</language><publisher>United States: e-Century Publishing Corporation</publisher><subject>Age Factors ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Bone Density - drug effects ; Bone Density Conservation Agents - adverse effects ; Bone Density Conservation Agents - therapeutic use ; Chi-Square Distribution ; Denosumab ; Female ; Humans ; Odds Ratio ; Original ; Osteoporosis, Postmenopausal - diagnosis ; Osteoporosis, Postmenopausal - drug therapy ; Osteoporosis, Postmenopausal - physiopathology ; Osteoporotic Fractures - diagnosis ; Osteoporotic Fractures - physiopathology ; Osteoporotic Fractures - prevention & control ; Risk Assessment ; Risk Factors ; Sex Factors ; Treatment Outcome</subject><ispartof>International journal of clinical and experimental pathology, 2014-01, Vol.7 (5), p.2113-2122</ispartof><rights>IJCEP Copyright © 2014 2014</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069896/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069896/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24966919$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Zhenyu</creatorcontrib><creatorcontrib>Chen, Chen</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><creatorcontrib>Ji, Xinran</creatorcontrib><creatorcontrib>Liu, Lifeng</creatorcontrib><creatorcontrib>Zhang, Guichun</creatorcontrib><creatorcontrib>Cao, Xuecheng</creatorcontrib><creatorcontrib>Wang, Pingshan</creatorcontrib><title>Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis</title><title>International journal of clinical and experimental pathology</title><addtitle>Int J Clin Exp Pathol</addtitle><description>The aim of this meta-analysis was to assess the safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density (BMD).
Safety of denosumab was compared with placebo or bisphosphonates. A systematic literature search without language restriction was conducted up to January, 2014. The RevMan 5.1 software was used for statistical analysis.
A total of 11 English literatures were eventually identified. The pooled data in the overall analysis revealed that there was no significant difference when compared denosumab with placebo or bisphosphonates in any adverse events (AAE) (RR=0.99, 95% CI=0.98-1.01, p=0.29), serious adverse event (SAE) (RR=1.05, 95% CI=0.98-1.13, p=0.18), neoplasm/cancer (RR=1.14, 95% CI=0.95-1.37, p=0.16) and deaths (RR=0.77, 95% CI=0.57-1.04, p=0.09). However, significant differences were found when compared denosumab with placebo or bisphosphonates in SAE related to infection (RR=1.23, 95% CI=1.00-1.52, p=0.05) and non-vertebral fracture (RR=0.86, 95% CI=0.74-1.00, p=0.05). Subgroup analysis was performed by the type of drugs which was used in the control group. The results of subgroup analysis did not demonstrate the differences between denosumab and bisphosphonates in SAE related to infection (RR=1.13, 95% CI=0.63-2.03) and non-vertebral fracture (RR=1.31, 95% CI=0.87-1.98).
Compared to placebo, denosumab treatment significantly decreased the risk of non-vertebral fracture but increased the risk of SAE related to infection in the postmenopausal women with osteoporosis or low BMD. However, no difference between the safety of denosumab and bisphosphonates was found.</description><subject>Age Factors</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Chi-Square Distribution</subject><subject>Denosumab</subject><subject>Female</subject><subject>Humans</subject><subject>Odds Ratio</subject><subject>Original</subject><subject>Osteoporosis, Postmenopausal - diagnosis</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Osteoporosis, Postmenopausal - physiopathology</subject><subject>Osteoporotic Fractures - diagnosis</subject><subject>Osteoporotic Fractures - physiopathology</subject><subject>Osteoporotic Fractures - prevention & control</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Sex Factors</subject><subject>Treatment Outcome</subject><issn>1936-2625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkFtLxDAQhYsg7rr6FyR_oJBLOyY-CLJ4WVjwQX0uaTJ1s7RJabIu_fcGvKBPw8w55-MwJ8WSKQElB14vivMY95QC4xU9Kxa8UgCKqWWxf9EdppmEjlj0IR4G3RLnyRhiGvJh1Ieoe3IMeSFHl3YkCxjGMIXoIgkT6cORtMEjGZzHKXszJ7o03xBNBky61F73czZfFKed7iNefs9V8fZw_7p-KrfPj5v13bYcOUAq4VrWSKm1zDDKjUBVCWlrAM1qqywqS4VsmbZQYQdKSZS1ocIIKpFTY8SquP3ijod2QGvQp1yrGSc36GlugnbNf8W7XfMePpqKgpIKMuDqL-A3-fM18QmfX2vY</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Zhou, Zhenyu</creator><creator>Chen, Chen</creator><creator>Zhang, Jun</creator><creator>Ji, Xinran</creator><creator>Liu, Lifeng</creator><creator>Zhang, Guichun</creator><creator>Cao, Xuecheng</creator><creator>Wang, Pingshan</creator><general>e-Century Publishing Corporation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>5PM</scope></search><sort><creationdate>20140101</creationdate><title>Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis</title><author>Zhou, Zhenyu ; Chen, Chen ; Zhang, Jun ; Ji, Xinran ; Liu, Lifeng ; Zhang, Guichun ; Cao, Xuecheng ; Wang, Pingshan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p266t-6785e00dd1c102c3e9438d566a15d9de9d038b1ad64ef6998e85c03c308e20cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Age Factors</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Chi-Square Distribution</topic><topic>Denosumab</topic><topic>Female</topic><topic>Humans</topic><topic>Odds Ratio</topic><topic>Original</topic><topic>Osteoporosis, Postmenopausal - diagnosis</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Osteoporosis, Postmenopausal - physiopathology</topic><topic>Osteoporotic Fractures - diagnosis</topic><topic>Osteoporotic Fractures - physiopathology</topic><topic>Osteoporotic Fractures - prevention & control</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Sex Factors</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Zhenyu</creatorcontrib><creatorcontrib>Chen, Chen</creatorcontrib><creatorcontrib>Zhang, Jun</creatorcontrib><creatorcontrib>Ji, Xinran</creatorcontrib><creatorcontrib>Liu, Lifeng</creatorcontrib><creatorcontrib>Zhang, Guichun</creatorcontrib><creatorcontrib>Cao, Xuecheng</creatorcontrib><creatorcontrib>Wang, Pingshan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of clinical and experimental pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Zhenyu</au><au>Chen, Chen</au><au>Zhang, Jun</au><au>Ji, Xinran</au><au>Liu, Lifeng</au><au>Zhang, Guichun</au><au>Cao, Xuecheng</au><au>Wang, Pingshan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis</atitle><jtitle>International journal of clinical and experimental pathology</jtitle><addtitle>Int J Clin Exp Pathol</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>7</volume><issue>5</issue><spage>2113</spage><epage>2122</epage><pages>2113-2122</pages><eissn>1936-2625</eissn><abstract>The aim of this meta-analysis was to assess the safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density (BMD).
Safety of denosumab was compared with placebo or bisphosphonates. A systematic literature search without language restriction was conducted up to January, 2014. The RevMan 5.1 software was used for statistical analysis.
A total of 11 English literatures were eventually identified. The pooled data in the overall analysis revealed that there was no significant difference when compared denosumab with placebo or bisphosphonates in any adverse events (AAE) (RR=0.99, 95% CI=0.98-1.01, p=0.29), serious adverse event (SAE) (RR=1.05, 95% CI=0.98-1.13, p=0.18), neoplasm/cancer (RR=1.14, 95% CI=0.95-1.37, p=0.16) and deaths (RR=0.77, 95% CI=0.57-1.04, p=0.09). However, significant differences were found when compared denosumab with placebo or bisphosphonates in SAE related to infection (RR=1.23, 95% CI=1.00-1.52, p=0.05) and non-vertebral fracture (RR=0.86, 95% CI=0.74-1.00, p=0.05). Subgroup analysis was performed by the type of drugs which was used in the control group. The results of subgroup analysis did not demonstrate the differences between denosumab and bisphosphonates in SAE related to infection (RR=1.13, 95% CI=0.63-2.03) and non-vertebral fracture (RR=1.31, 95% CI=0.87-1.98).
Compared to placebo, denosumab treatment significantly decreased the risk of non-vertebral fracture but increased the risk of SAE related to infection in the postmenopausal women with osteoporosis or low BMD. However, no difference between the safety of denosumab and bisphosphonates was found.</abstract><cop>United States</cop><pub>e-Century Publishing Corporation</pub><pmid>24966919</pmid><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1936-2625 |
| ispartof | International journal of clinical and experimental pathology, 2014-01, Vol.7 (5), p.2113-2122 |
| issn | 1936-2625 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4069896 |
| source | MEDLINE; PubMed Central; EZB Electronic Journals Library |
| subjects | Age Factors Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Bone Density - drug effects Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Chi-Square Distribution Denosumab Female Humans Odds Ratio Original Osteoporosis, Postmenopausal - diagnosis Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology Osteoporotic Fractures - diagnosis Osteoporotic Fractures - physiopathology Osteoporotic Fractures - prevention & control Risk Assessment Risk Factors Sex Factors Treatment Outcome |
| title | Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T16%3A00%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20denosumab%20in%20postmenopausal%20women%20with%20osteoporosis%20or%20low%20bone%20mineral%20density:%20a%20meta-analysis&rft.jtitle=International%20journal%20of%20clinical%20and%20experimental%20pathology&rft.au=Zhou,%20Zhenyu&rft.date=2014-01-01&rft.volume=7&rft.issue=5&rft.spage=2113&rft.epage=2122&rft.pages=2113-2122&rft.eissn=1936-2625&rft_id=info:doi/&rft_dat=%3Cpubmed%3E24966919%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24966919&rfr_iscdi=true |